Vertex - Near Term Positive Long Term Neutral

September 2011 | 5 pages | ID: VF2BB54238CEN
MP Advisors

Abstracts

While competition in the HCV therapy area is heating up, Vertex (VRTX) will continue to have the edge for at least 3yrs. We expect most of the near term milestones related for Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. CF compound has shown impressive data in niche population, RA program can get a significant market share despite…. For more details, please read our report released on 23th September, 2011 on VRTX titled “Near Term Positive Long Term Neutral”.

Contents

COMPANIES MENTIONED

VERTEX